ClinicalTrials.gg
CompletedNCT00878189Updated Nov 12, 2019Results posted

A Trial In Patients With Advanced Cancer And Leukemia

A Phase 1 interventional study of PF-03084014 in Neoplasms by Histologic Type, sponsored by Pfizer. Completed at 10 sites in 2 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.

Primary conditionLeukemiaRegistry: Neoplasms by Histologic TypeReclassifiedWhy we changed it
Registry
Neoplasms by Histologic Type — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia
Why
  1. The study's title name Leukemia, a narrower term within Neoplasms by Histologic Type.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Leukemia by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Leukemia · Pfizer.

Enrollment
9th of 17
72 · median 72
Started
2009
the only one that year
Phase 1
4 of 19
none open now
Registered
14th of 19
by date

Among the 19 studies in Leukemia by Pfizer, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 1, and was the 14th registered.

Leukemia

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

Browse Leukemia studies →

Open to participants now

1 of the 19 studies in Leukemia by Pfizer is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Leukemia by Pfizer, or all of them as a file.
02

Study summary

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

03

Conditions studied

  • Neoplasms by Histologic Type

Browse trials for

Keywords

  • Phase 1 dose escalation study in advanced solid tumor malignancy and leukemia
04

In context

Leukemia Reclassified

2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.

This study's enrollment of 72 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.

Browse Leukemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Leukemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms by Histologic Type. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available
  • Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available
  • Men and women >16 years old

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a gamma secretase inhibitor for treatment of cancer
  • Patients taking Tamoxifen
  • Patients with active
  • Known (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  • Patients who are pregnant or breast feeding
  • Patients with clinical evidence of central nervous system disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    1

    Drug: PF-03084014

Interventions

  • 10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily

    Also known as: gamma secretase inhibitor

07

What researchers measure

Primary outcomes

  1. Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)

    Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding

    Time frame: Baseline to the end of Cycle 1 (Week 4)

  2. Number of T-ALL/LBL Participants With First-Cycle DLT

    Any DLT attributable to PF-03084014 at 1st Cycle: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days; unable to deliver at least 80% of planned dose; absolute neutrophil count (ANC) \<1000/microliter (uL), or platelet count \<30,000/uL, or hemoglobin \<8 gram/deciliter (g/dL) in a bone marrow with \<5% blasts and no evidence of leukemia or abnormal dysplasia for \>42 days

    Time frame: Baseline to the end of Cycle 1 (Week 4)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of casual relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.

    Time frame: Baseline up to end of study (maximum of 84 months)

  2. Number of Participants With TEAEs (Treatment-Related)

    An AE was any untoward medical occurrence in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.

    Time frame: Baseline up to end of study (maximum of 84 months)

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality) by Severity (by Maximum Common Terminology Criteria for Adverse Events [CTCAE] Grade)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.

    Time frame: Baseline up to end of study (maximum of 84 months)

  4. Number of Participants With TEAEs (Treatment-Related) by Severity (by Maximum CTCAE Grade)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.

    Time frame: Baseline up to end of study (maximum of 84 months)

  5. Number of Participants With Potentially Clinical Significant Categorical Changes From Baseline in Electrocardiogram (ECG) Findings in QTc Interval

    Criteria for potentially important changes in ECG were defined as: maximum (max.) post-dose (post-baseline) time from electrocardiogram Q wave to the corresponding to electrical systole (QT interval) corrected for Fridericia's factor (QTcF), or QT interval corrected for Bazett's factor (QTcB): \<450, 450 -\<480, 480-\<500, and \>=500 msec. Maximum increase (inc.) from baseline in QTcF or QTcB: change (chg) \<30, 30\>=chg\<60, and chg \>=60 msec.

    Time frame: Baseline up to end of study (maximum of 84 months)

  6. Number of Participants With Laboratory Tests Abnormalities Meeting the Criteria of Potential Clinical Concern (Hematology and Chemistries, All Cycles)

    Parameters analyzed included: white blood cell (WBC) count plus differential, absolute (abs) neutrophil count, platelets, hemoglobin, sodium, potassium, bicarbonate, chloride, blood urea nitrogen, creatinine, glucose, uric acid, calcium, phosphate, magnesium, total protein, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), partial prothrombin time/international normalized ratio (PTT/INR). Urinalysis: pH, specific gravity, protein, glucose, ketones, blood, leukocyte esterase, and nitrites. Pregnancy test: Serum or urine pregnancy test for women of childbearing potential. There were no changes in urine protein among the solid tumor and T-ALL/LBL participants that were clinically significant. Clinical significance was judged by the investigator.

    Time frame: Baseline up to end of study (maximum of 84 months)

  7. Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1

    Cmax was the maximum observed serum concentration.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)

  8. Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1

    Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)

  9. Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1

    AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). CV is the coefficient of variation.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)

  10. Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1

    AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. NE is not estimable.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)

  11. Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1

    Tmax was the time to reach maximum serum concentration (Cmax).

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)

  12. Cmax After Multiple Dose on Cycle 1 Day 21

    Cmax was the maximum observed serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant. CV is the coefficient of variation.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  13. Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21

    Tmax was the time to reach maximum serum concentration (Cmax). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  14. AUCtau After Multiple Dose on Cycle 1 Day 21

    AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  15. Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 21

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  16. Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21

    Serum decay half-life (t1/2) is the time measured for the serum concentration to decrease by one half. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  17. Apparent Oral Clearance (CL/F) on Cycle 1 Day 21

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  18. Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21

    Cmin was the minimum serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  19. Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21

    Cavg was the average serum concentration at steady state. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  20. Accumulation Ratio (Rac) on Cycle 1 Day 21

    Accumulation was calculated as AUCtau at steady state (Cycle 1 Day 21) divided by AUCtau after a single dose on Cycle 1 Day 1. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose), Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  21. Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21

    AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  22. Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21

    Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

    Time frame: Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)

  23. AUCtau in the Fasted State for Solid Tumor Participants

    AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  24. AUCtau in the Fed State for Solid Tumor Participants

    AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  25. Cmax in the Fasted State for Solid Tumor Participants

    Cmax was the maximum observed serum concentration.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  26. Cmax in the Fed State for Solid Tumor Participants

    Cmax was the maximum observed serum concentration.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  27. Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants

    AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  28. Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants

    AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  29. Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants

    Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  30. Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants

    Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

    Time frame: Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose).

  31. AUCtau on Cycle 2 Day 1

    AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  32. Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1

    AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  33. Cmax on Cycle 2 Day 1

    Cmax was the maximum observed serum concentration. Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  34. Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1

    Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  35. Tmax on Cycle 2 Day 1

    Tmax was the time to reach maximum serum concentration (Cmax). Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)

  36. Percentage of Solid Tumor Participants With Objective Response (OR)

    Objective response (OR) was defined as confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \>=30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (plus [+] or minus [-] 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles

  37. Time to Tumor Progression (TTP) for Solid Tumor Participants

    Time from Cycle 1 Day 1 to first documentation of disease progression. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, uneuivocal progression of non-target disease, or the appearance of new lesions. TTP (months) was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.

    Time frame: Baseline until first documented objective progression (up to maximum of 84 months)

  38. Duration of Response (DR) for Solid Tumor Participants

    Time from the first documentation of OR to objective disease progression or death due to any cause. DR was only calculated for participants with an OR. DR (months) was calculated as (date of first documentation of objective progression or death minus date of first documentation of PR or CR plus 1) divided by 30.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or -5 days) of every odd cycle or as clinically indicated, up to Cycle 9. Afterwards, assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)

  39. Progression-Free Survival (PFS) for Solid Tumor Participants

    PFS was defined as the time from Cycle 1 Day 1 to date of first documentation of progression or death due to any cause. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions. PFS (months) was calculated as (the first event date minus the date of first dose of study medication plus 1) divided by 30.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)

  40. Percentage of T-ALL/LBL Participants With OR

    OR was adapted from International Working Group Response Criteria for Acute Myeloid Leukemia (AML). The response categories of interest were CR, complete response with incomplete hematopoietic recovery (CRi), and PR. CR: ANC \>1500/microliter (uL), no circulating blasts. Platelets \>100,000/uL, \<5% marrow blast cells, no extramedullary disease, bone marrow cellularity \>20% with tri-lineage hematopoiesis and \<5% marrow blast cells, none of which were neoplastic; CRi: same as CR but ANC may be \>1500/uL or platelet count \>100,000/uL, no requirement on bone marrow cellularity; PR: same as CR but bone marrow with \>= 50% reduction of leukemia blast cells and an absolute blast count between 5% and 25%.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)

  41. Relapse Free Survival (RFS) for T-ALL/LBL Participants

    The RFS of CR was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first. Similarly, the RFS of CR + CRi (or RFS of CR + CRi + PR) was defined as the time from the date of first attaining CR + CRi (or CR + CRi + PR) to the date of relapse or death from any cause, whichever occurred first.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)

  42. Peripheral Blast Count Reduction (PBR) for T-ALL/LBL Participants

    PBR was the maximum percentage of peripheral blast count reduction for each participant who received at least one dose of study medication. PBR was derived by the Sponsor from percentage of peripheral blood Blast Count reported by sites.

    Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)

  43. Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline

    Gene expression analysis in tumor biopsies was done using cDNA prepared from RNA extracted from tumor biopsies. Gene expression was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Only Hes4 gene showed consistent down modulation across dosing cohorts (150 mg and 220 mg BID) and therefore results were reported for Hes4 only. Data for this outcome measure was planned to be analyzed for two arms only.

    Time frame: Baseline, Cycle 1 Day 21 (-5 days)

  44. Changes From Baseline in Expression Levels of Notch 1 Target Genes in Peripheral Blood for T-ALL/LBL Participants: Hes4 Gene Expression Levels on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 21 Relative to That at Baseline

    Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).

    Time frame: Baseline (morning), Cycle 1 Days 8, 15 and 21 (morning, matched with the first PK sample of the particular day), Cycle 1 Day 21 (24, 48, and 120 hr post-dose) and at end of treatment (EOT)

  45. Changes in Expression Levels of Notch 1 Target Genes in Peripheral Blood for Solid Tumor Participants: Hes4 Gene Expression Level on Cycle 1 Day 8 and Cycle 1 Day 21 Relative to That at Baseline

    Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).

    Time frame: Baseline (morning), Cycle 1 Days 8 and 21 (pre-dose)

  46. Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Peripheral Blood for T-ALL/LBL Participants

    Notch intracellular domain (NICD) levels was measured in peripheral blood mononuclear cell (PBMC) pellets using a validated enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline, Cycle 1 Days 8 and 15 (pre-dose AM), Cycle 1 Day 21 (pre-dose AM and 24, 48 and 120 hr post-dose) and end of treatment (EOT).

  47. Changes From Baseline in Notch Intracellular Domain (NICD) Levels in Bone Marrow for T-ALL/LBL Participants

    Notch intracellular domain (NICD) was to be measured in bone marrow monoculear cell (BMMC) cell pellets using a validated ELISA.

    Time frame: Baseline, Cycle 1 Day 1 and Cycle 2 Day 1

08

Results

Posted Nov 12, 2019
Limitations and caveats
Study components related to combination therapy with dexamethasone were removed due to operational/scientific reasons. Due to halting of T-AA/LBL participant's enrollment; limited number of evaluable participants, PBR and RFS data was not collected.

Participant flow

This study originally planned to give PF-03084014 in combination with dexamethasone in participants with solid tumors and with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma, including a drug-drug-interaction test of PF-03084014 and dexamethasone in solid tumor participants. But these parts were removed per protocol amendments.

Participant flow — Overall Study
MilestonePF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Started33484231638
Completed000000000
Not completed33484231638
Withdrew: Death010100001
Withdrew: Participant refused to follow-up000004000
Withdrew: Other32474181534
Withdrew: Lost to follow-up000001100
Withdrew: Objection progression or relapse000000003

Outcome measures

PrimaryNumber of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)

Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding

Time frame:
Baseline to the end of Cycle 1 (Week 4)
Reported as:
Number · participants
Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Number of Solid Tumor Participants With First-Cycle Dose-Limiting Toxicity (DLT)00010112
PrimaryNumber of T-ALL/LBL Participants With First-Cycle DLT

Any DLT attributable to PF-03084014 at 1st Cycle: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days; unable to deliver at least 80% of planned dose; absolute neutrophil count (ANC) \<1000/microliter (uL), or platelet count \<30,000/uL, or hemoglobin \<8 gram/deciliter (g/dL) in a bone marrow with \<5% blasts and no evidence of leukemia or abnormal dysplasia for \>42 days

Time frame:
Baseline to the end of Cycle 1 (Week 4)
Reported as:
Number · participants
Number of T-ALL/LBL Participants With First-Cycle DLT
participantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Number of T-ALL/LBL Participants With First-Cycle DLT1
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of casual relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality)
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
No. of Participants With AEs33474231638
No. of Participants With SAEs112428724
No. of Participants Discontinued PF-03084014010211423
No. of Participants Temp. Discontinued Treatment112119510
No. of Participants With Dose Reduction Due to AEs000014311
SecondaryNumber of Participants With TEAEs (Treatment-Related)

An AE was any untoward medical occurrence in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. An SAE was any untoward medical occurrence at any dose that: resulted in death, was life-threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), and resulted in congenital anomaly/birth defect.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With TEAEs (Treatment-Related)
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
No. of Participants With AEs21264201635
No. of Participants With SAEs000110101
No. of Participants Discontinued PF-03084014000101110
No. of Participants Temp. Discontinued Treatment000017410
No.of Participants With Dose Reduction Due to AEs000014311
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality) by Severity (by Maximum Common Terminology Criteria for Adverse Events [CTCAE] Grade)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causality) by Severity (by Maximum Common Terminology Criteria for Adverse Events [CTCAE] Grade)
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Any AEs, Grade 1001101101
Any AEs, Grade 2210128301
Any AEs, Grade 31122212924
Any AEs, Grade 4001202111
Any AEs, Grade 5010100201
SecondaryNumber of Participants With TEAEs (Treatment-Related) by Severity (by Maximum CTCAE Grade)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-related events were those assessed by the investigator as related to study medication. CTCAE version 3.0 was used for AE grading: Grade 1 mild AE; Grade 2 moderate AE; Grade 3 severe AE; Grade 4 life-threatening or disabling AE; Grade 5 death related to AE.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With TEAEs (Treatment-Related) by Severity (by Maximum CTCAE Grade)
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Any AEs, Grade 1101116203
Any AEs, Grade 2110326410
Any AEs, Grade 30011181021
Any AEs, Grade 4000100000
Any AEs, Grade 5000000000
Missing or Unknown000000001
SecondaryNumber of Participants With Potentially Clinical Significant Categorical Changes From Baseline in Electrocardiogram (ECG) Findings in QTc Interval

Criteria for potentially important changes in ECG were defined as: maximum (max.) post-dose (post-baseline) time from electrocardiogram Q wave to the corresponding to electrical systole (QT interval) corrected for Fridericia's factor (QTcF), or QT interval corrected for Bazett's factor (QTcB): \<450, 450 -\<480, 480-\<500, and \>=500 msec. Maximum increase (inc.) from baseline in QTcF or QTcB: change (chg) \<30, 30\>=chg\<60, and chg \>=60 msec.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With Potentially Clinical Significant Categorical Changes From Baseline in Electrocardiogram (ECG) Findings in QTc Interval
participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Max. QTcB interval <450 msec0324211528
Max. QTcB interval 450-<480 msec301328918
Max. QTcB interval 480-<500 msec000104008
Max. QTcB interval >=500 msec001000208
Max. QTcF interval <450 msec33273131238
Max. QTcF interval 450-<480 msec001019200
Max. QTcF interval 480-<500 msec000101000
Max. QTcF interval >=500 msec001000200
Max. QTcB interval inc. from baseline chg<30 msec1217321737
Max. QTcB interval inc. from baseline 30=<chg<60212112701
Max. QTcB interval inc. from baseline chg>=60 msec001000200
Max. QTcF interval inc. from baseline chg<30 msec32173221238
Max. QTcF interval inc. from baseline 30=<chg<60012111200
Max. QTcF interval inc. from baseline chg>=60 msec001000200
SecondaryNumber of Participants With Laboratory Tests Abnormalities Meeting the Criteria of Potential Clinical Concern (Hematology and Chemistries, All Cycles)

Parameters analyzed included: white blood cell (WBC) count plus differential, absolute (abs) neutrophil count, platelets, hemoglobin, sodium, potassium, bicarbonate, chloride, blood urea nitrogen, creatinine, glucose, uric acid, calcium, phosphate, magnesium, total protein, albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), partial prothrombin time/international normalized ratio (PTT/INR). Urinalysis: pH, specific gravity, protein, glucose, ketones, blood, leukocyte esterase, and nitrites. Pregnancy test: Serum or urine pregnancy test for women of childbearing potential. There were no changes in urine protein among the solid tumor and T-ALL/LBL participants that were clinically significant. Clinical significance was judged by the investigator.

Time frame:
Baseline up to end of study (maximum of 84 months)
Reported as:
Number · participants
Number of Participants With Laboratory Tests Abnormalities Meeting the Criteria of Potential Clinical Concern (Hematology and Chemistries, All Cycles)
participantsPF-03084014 in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Hemoglobin458
Lymphocytes (abs)408
Neutrophils (abs)45
Platelets136
WBC45
ALT224
ALP243
AST324
Bicarbonate151
Bilirubin102
Creatinine171
Hypercalcaemia170
Hyperglycaemia556
Hyperkalaemia40
Hypermagnesaemia10
Hypernatraemia40
Hypoalbuminaemia436
Hypocalcaemia186
Hypoglycaemia60
Hypokalaemia234
Hypomagnesaemia81
Hyponatraemia193
Hypophosphataemia544
SecondaryMaximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1

Cmax was the maximum observed serum concentration.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1
nanogram/milliliter (ng/mL)PF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Maximum Observed Serum Concentration (Cmax) After a Single Dose on Cycle 1 Day 1163 ± 62368 ± 48230 ± 193691 ± 37536 ± 72943 ± 100861 ± 631892 ± 541604 ± 85
SecondaryDose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1

Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Reported as:
Geometric mean · ng/mL/mg
Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 1
ng/mL/mgPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Dose-normalized Cmax [Cmax (dn)] After a Single Dose on Cycle 1 Day 18.1 ± 639.2 ± 482.9 ± 1936.9 ± 374.1 ± 726.3 ± 1003.9 ± 635.7 ± 5410.7 ± 85
SecondaryArea Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1

AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). CV is the coefficient of variation.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1
nanogram*hour/milliliter (ng*hr/mL)PF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Area Under the Time-Concentration Curve From Time 0 to the Dosing Interval (AUCtau) After a Single Dose on Cycle 1 Day 1409 ± 831329 ± 871649 ± 982204 ± 372924 ± 813677 ± 863593 ± 588014 ± NA6412 ± 80
SecondaryDose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1

AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. NE is not estimable.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL/mg
Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 1
ng*hr/mL/mgPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Dose-normalized AUCtau [AUCtau (dn) ] After a Single Dose on Cycle 1 Day 120.4 ± 8333.2 ± 8720.6 ± 9822.0 ± 3722.5 ± 8124.5 ± 8616.3 ± 5824.3 ± NA42.7 ± 80
SecondaryTime to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1

Tmax was the time to reach maximum serum concentration (Cmax).

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose)
Reported as:
Median · hours
Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 1
hoursPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Time to Reach Cmax (Tmax) After a Single Dose on Cycle 1 Day 11.0 (0.9 to 1.0)1.0 (1.0 to 1.3)2.0 (1.0 to 8.0)1.0 (1.0 to 2.0)2.5 (1.0 to 4.0)1.1 (0.5 to 4.1)2.0 (1.0 to 4.1)1.2 (1.0 to 2.0)1.1 (0.9 to 4.0)
SecondaryCmax After Multiple Dose on Cycle 1 Day 21

Cmax was the maximum observed serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant. CV is the coefficient of variation.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng/mL
Cmax After Multiple Dose on Cycle 1 Day 21
ng/mLPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Cmax After Multiple Dose on Cycle 1 Day 2164.5 ± NA381 ± NA313 ± 29867 ± 44421 ± 1301246 ± 791864 ± 761828 ± 42
SecondaryTime to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21

Tmax was the time to reach maximum serum concentration (Cmax). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Median · hour
Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 21
hourPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Time to Reach Cmax (Tmax) After Multiple Dose on Cycle 1 Day 211.1 (1.0 to 1.1)1.0 (1.0 to 1.0)1.1 (1.0 to 4.0)1.0 (1.0 to 2.7)3.7 (1.0 to 8.0)1.1 (1.0 to 4.0)1.0 (0.5 to 2.0)1.6 (1.0 to 2.0)
SecondaryAUCtau After Multiple Dose on Cycle 1 Day 21

AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL
AUCtau After Multiple Dose on Cycle 1 Day 21
ng*hr/mLPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
AUCtau After Multiple Dose on Cycle 1 Day 21309.0 ± NA2521 ± NA1572 ± 424741 ± 703155 ± 596430 ± 8910520 ± 899161 ± 30
SecondaryApparent Volume of Distribution (Vz/F) on Cycle 1 Day 21

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired concentration of a drug. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · liter (L)
Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 21
liter (L)PF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Apparent Volume of Distribution (Vz/F) on Cycle 1 Day 212810 ± NA516 ± NA3353 ± NA986 ± 522048 ± 49801 ± 144852 ± 120424 ± 61
SecondarySerum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21

Serum decay half-life (t1/2) is the time measured for the serum concentration to decrease by one half. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Mean · hours
Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 21
hoursPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Serum Decay Half-Life (t1/2) After Multiple Dose on Cycle 1 Day 2130.3 ± NA22.6 ± NA38.6 ± NA34.2 ± 11.734.7 ± 5.325.3 ± 9.229.3 ± 9.318.0 ± 3.6
SecondaryApparent Oral Clearance (CL/F) on Cycle 1 Day 21

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · liter/hour (L/hr)
Apparent Oral Clearance (CL/F) on Cycle 1 Day 21
liter/hour (L/hr)PF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Apparent Oral Clearance (CL/F) on Cycle 1 Day 2164.8 ± NA15.9 ± NA50.9 ± 4221.1 ± 7041.2 ± 5923.4 ± 8820.9 ± 8916.4 ± 30
SecondaryMinimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21

Cmin was the minimum serum concentration. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng/mL
Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 21
ng/mLPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Minimum Observed Serum Concentration (Cmin) After Multiple Dose on Cycle 1 Day 2110.7 ± NA126 ± NA59.2 ± 103232 ± 118206 ± 40266 ± 102469 ± 118420 ± 81
SecondaryAverage Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21

Cavg was the average serum concentration at steady state. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng/mL
Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 21
ng/mLPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Average Serum Concentration (Cavg) at Steady State on Cycle 1 Day 2125.7 ± NA210 ± NA131 ± 42395 ± 69263 ± 59536 ± 89877 ± 89763 ± 30
SecondaryAccumulation Ratio (Rac) on Cycle 1 Day 21

Accumulation was calculated as AUCtau at steady state (Cycle 1 Day 21) divided by AUCtau after a single dose on Cycle 1 Day 1. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, and 10 hr post-dose), Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Median · ratio
Accumulation Ratio (Rac) on Cycle 1 Day 21
ratioPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Accumulation Ratio (Rac) on Cycle 1 Day 211.18 (0.72 to 1.63)1.60 (1.45 to 1.74)1.36 (0.93 to 1.79)2.49 (1.23 to 2.86)1.98 (1.81 to 2.15)2.29 (0.95 to 4.90)2.84 (1.14 to 5.80)0.97 (NA to NA)
SecondaryDose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21

AUCtau (dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL/mg
Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 21
ng*hr/mL/mgPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Dose-normalized AUCtau [AUCtau (dn)] After Multiple Dose on Cycle 1 Day 2115.4 ± NA63.0 ± NA19.7 ± 4147.4 ± 7024.3 ± 5942.9 ± 8847.9 ± 8961.1 ± 30
SecondaryDose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21

Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Cycle 1 Day 21 PK parameter summaries are presented only for participants who were considered to be dose compliant.

Time frame:
Cycle 1 Day 21 (pre-dose and 0.5, 1, 2, 4, 10, 24, 48, 96 and 120 hr post-dose)
Reported as:
Geometric mean · ng/mL/mg
Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 21
ng/mL/mgPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Dose-normalized Cmax [Cmax (dn)] After Multiple Dose on Cycle 1 Day 213.2 ± NA9.6 ± NA3.9 ± 298.7 ± 443.2 ± 1308.3 ± 798.5 ± 7612.2 ± 42
SecondaryAUCtau in the Fasted State for Solid Tumor Participants

AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL
AUCtau in the Fasted State for Solid Tumor Participants
ng*hr/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
AUCtau in the Fasted State for Solid Tumor Participants2547 ± 1019353 ± 100
SecondaryAUCtau in the Fed State for Solid Tumor Participants

AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval).

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL
AUCtau in the Fed State for Solid Tumor Participants
ng*hr/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
AUCtau in the Fed State for Solid Tumor Participants3163 ± 835573 ± 39
SecondaryCmax in the Fasted State for Solid Tumor Participants

Cmax was the maximum observed serum concentration.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng/mL
Cmax in the Fasted State for Solid Tumor Participants
ng/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Cmax in the Fasted State for Solid Tumor Participants795.1 ± 1042334 ± 93
SecondaryCmax in the Fed State for Solid Tumor Participants

Cmax was the maximum observed serum concentration.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng/mL
Cmax in the Fed State for Solid Tumor Participants
ng/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Cmax in the Fed State for Solid Tumor Participants862.3 ± 74924.4 ± 40
SecondaryDose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants

AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL/mg
Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants
ng*hr/mL/mgPF-03084014 in Solid Tumor Participants
Dose-normalized AUCtau [AUCtau(dn)] in the Fasted State for Solid Tumor Participants23.71 ± 115
SecondaryDose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants

AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL/mg
Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants
ng*hr/mL/mgPF-03084014 in Solid Tumor Participants
Dose-normalized AUCtau [AUCtau(dn)] in the Fed State for Solid Tumor Participants22.54 ± 67
SecondaryDose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants

Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng/mL/mg
Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants
ng/mL/mgPF-03084014 in Solid Tumor Participants
Dose-normalized Cmax [Cmax(dn)] in the Fasted State for Solid Tumor Participants6.56 ± 106
SecondaryDose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants

Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose.

Time frame:
Cycle 1 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose) or Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose).
Reported as:
Geometric mean · ng/mL/mg
Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants
ng/mL/mgPF-03084014 in Solid Tumor Participants
Dose-Normalized Cmax [Cmax(dn)] in the Fed State for Solid Tumor Participants5.22 ± 64
SecondaryAUCtau on Cycle 2 Day 1

AUCtau was area under the serum concentration-time profile from time 0 to tau (dosing interval). Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL
AUCtau on Cycle 2 Day 1
ng*hr/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
AUCtau on Cycle 2 Day 12784 ± 8011870 ± 57
SecondaryDose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1

AUCtau(dn) was calculated by area under the serum concentration-time profile from time 0 to tau (dosing interval) (AUCtau) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng*hr/mL/mg
Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 1
ng*hr/mL/mgPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Dose-normalized AUCtau [AUCtau (dn)] on Cycle 2 Day 118.6 ± 8054.0 ± 57
SecondaryCmax on Cycle 2 Day 1

Cmax was the maximum observed serum concentration. Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng/mL
Cmax on Cycle 2 Day 1
ng/mLPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Cmax on Cycle 2 Day 1834.6 ± 762640 ± 63
SecondaryDose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1

Cmax(dn) was calculated by maximum observed serum concentration (Cmax) divided by administered dose. Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Geometric mean · ng/mL/mg
Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 1
ng/mL/mgPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Dose-normalized Cmax [Cmax (dn)] on Cycle 2 Day 15.6 ± 7612.0 ± 63
SecondaryTmax on Cycle 2 Day 1

Tmax was the time to reach maximum serum concentration (Cmax). Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Cycle 2 Day 1 (pre-dose and 0.5, 1, 2, 4, 10 and 24 hr post-dose)
Reported as:
Median · hr
Tmax on Cycle 2 Day 1
hrPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Tmax on Cycle 2 Day 12.00 (1.00 to 4.03)1.53 (0.98 to 4.00)
SecondaryPercentage of Solid Tumor Participants With Objective Response (OR)

Objective response (OR) was defined as confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \>=30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \>=4 weeks after initial documentation of response.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (plus [+] or minus [-] 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles
Reported as:
Number · percentage of participants
Percentage of Solid Tumor Participants With Objective Response (OR)
percentage of participantsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Percentage of Solid Tumor Participants With Objective Response (OR)33.3 (0.8 to 90.6)0 (0.0 to 70.8)66.7 (9.4 to 99.2)0 (0.0 to 52.2)0 (0.0 to 70.8)5.6 (0.1 to 27.3)10.0 (0.3 to 44.5)100 (2.5 to 100.0)
SecondaryTime to Tumor Progression (TTP) for Solid Tumor Participants

Time from Cycle 1 Day 1 to first documentation of disease progression. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, uneuivocal progression of non-target disease, or the appearance of new lesions. TTP (months) was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.

Time frame:
Baseline until first documented objective progression (up to maximum of 84 months)
Reported as:
Median · months
Time to Tumor Progression (TTP) for Solid Tumor Participants
monthsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Time to Tumor Progression (TTP) for Solid Tumor ParticipantsNA (0.8 to NA)1.2 (1.0 to 2.8)NA (1.7 to NA)3.1 (1.0 to NA)4.3 (1.6 to 19.5)1.6 (1.4 to 6.0)1.5 (1.1 to 4.2)NA (NA to NA)
SecondaryDuration of Response (DR) for Solid Tumor Participants

Time from the first documentation of OR to objective disease progression or death due to any cause. DR was only calculated for participants with an OR. DR (months) was calculated as (date of first documentation of objective progression or death minus date of first documentation of PR or CR plus 1) divided by 30.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or -5 days) of every odd cycle or as clinically indicated, up to Cycle 9. Afterwards, assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)
Reported as:
Median · months
Duration of Response (DR) for Solid Tumor Participants
monthsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Duration of Response (DR) for Solid Tumor ParticipantsNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryProgression-Free Survival (PFS) for Solid Tumor Participants

PFS was defined as the time from Cycle 1 Day 1 to date of first documentation of progression or death due to any cause. Progression was defined as per RECIST version 1.0, as a 20% increase in the sum of the longest diameter of target lesions, or target lesions over nadir, unequivocal progression of non-target disease, or the appearance of new lesions. PFS (months) was calculated as (the first event date minus the date of first dose of study medication plus 1) divided by 30.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9; afterwards assessed on Day 1 (+ or -5 days) every 4 cycles (up to maximum of 84 months)
Reported as:
Median · months
Progression-Free Survival (PFS) for Solid Tumor Participants
monthsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Progression-Free Survival (PFS) for Solid Tumor ParticipantsNA (0.8 to NA)1.2 (1.0 to 2.8)NA (1.7 to NA)2.3 (0.4 to NA)4.3 (1.6 to 19.5)1.6 (1.4 to 6.0)1.5 (1.1 to 4.2)NA (NA to NA)
SecondaryPercentage of T-ALL/LBL Participants With OR

OR was adapted from International Working Group Response Criteria for Acute Myeloid Leukemia (AML). The response categories of interest were CR, complete response with incomplete hematopoietic recovery (CRi), and PR. CR: ANC \>1500/microliter (uL), no circulating blasts. Platelets \>100,000/uL, \<5% marrow blast cells, no extramedullary disease, bone marrow cellularity \>20% with tri-lineage hematopoiesis and \<5% marrow blast cells, none of which were neoplastic; CRi: same as CR but ANC may be \>1500/uL or platelet count \>100,000/uL, no requirement on bone marrow cellularity; PR: same as CR but bone marrow with \>= 50% reduction of leukemia blast cells and an absolute blast count between 5% and 25%.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)
Reported as:
Number · percentage of participants
Percentage of T-ALL/LBL Participants With OR
percentage of participantsPF-03084014 150 mg BID in T-ALL/LBL Participants
Percentage of T-ALL/LBL Participants With OR12.5 (0.3 to 52.7)
SecondaryRelapse Free Survival (RFS) for T-ALL/LBL Participants

The RFS of CR was defined as the time from the date of first attaining CR to the date of relapse or death from any cause, whichever occurred first. Similarly, the RFS of CR + CRi (or RFS of CR + CRi + PR) was defined as the time from the date of first attaining CR + CRi (or CR + CRi + PR) to the date of relapse or death from any cause, whichever occurred first.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)

No measurements were reported for this outcome.

SecondaryPeripheral Blast Count Reduction (PBR) for T-ALL/LBL Participants

PBR was the maximum percentage of peripheral blast count reduction for each participant who received at least one dose of study medication. PBR was derived by the Sponsor from percentage of peripheral blood Blast Count reported by sites.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or - 5 days) of every odd cycle or as clinically indicated, up to Cycle 9 (up to maximum of 84 months)

No measurements were reported for this outcome.

SecondaryChanges in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline

Gene expression analysis in tumor biopsies was done using cDNA prepared from RNA extracted from tumor biopsies. Gene expression was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Only Hes4 gene showed consistent down modulation across dosing cohorts (150 mg and 220 mg BID) and therefore results were reported for Hes4 only. Data for this outcome measure was planned to be analyzed for two arms only.

Time frame:
Baseline, Cycle 1 Day 21 (-5 days)
Reported as:
Mean · ratio
Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline
ratioPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Changes in Expression Levels of Notch 1 Target Genes in Tumor Biopsies for Solid Tumor Participants: Hairy and Enhancer of Split-4 (Hes4) Gene Expression Levels on Cycle 1 Day 21 Relative to That at Baseline0.9 ± 0.570.5 ± 0.50
SecondaryChanges From Baseline in Expression Levels of Notch 1 Target Genes in Peripheral Blood for T-ALL/LBL Participants: Hes4 Gene Expression Levels on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 21 Relative to That at Baseline

Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).

Time frame:
Baseline (morning), Cycle 1 Days 8, 15 and 21 (morning, matched with the first PK sample of the particular day), Cycle 1 Day 21 (24, 48, and 120 hr post-dose) and at end of treatment (EOT)
Reported as:
Mean · ratio
Changes From Baseline in Expression Levels of Notch 1 Target Genes in Peripheral Blood for T-ALL/LBL Participants: Hes4 Gene Expression Levels on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 1 Day 21 Relative to That at Baseline
ratioPF-03084014 150 mg BID in T-ALL/LBL Participants
Cycle 1 Day 80.7 ± 0.65
Cycle 1 Day 150.3 ± 0.41
Cycle 1 Day 210.4 ± 0.27
EOT2.0 ± NA
SecondaryChanges in Expression Levels of Notch 1 Target Genes in Peripheral Blood for Solid Tumor Participants: Hes4 Gene Expression Level on Cycle 1 Day 8 and Cycle 1 Day 21 Relative to That at Baseline

Ribonucleic acid (RNA) was extracted from peripheral blood and used as a template to synthesize complementary deoxyribonucleic acid (cDNA). Gene expression in cDNA was measured by custom Taqman low density array (TLDA) cards run on Applied Biosystems 7900HT Fast Real-Time polymerase chain reaction (PCR) system. Changes from baseline were calculated as ratios to baseline. Results were reported Only for Hes4 as this was the only gene to show consistent down modulation across dosing cohorts (150 mg and 220 mg).

Time frame:
Baseline (morning), Cycle 1 Days 8 and 21 (pre-dose)
Reported as:
Mean · ratio
Changes in Expression Levels of Notch 1 Target Genes in Peripheral Blood for Solid Tumor Participants: Hes4 Gene Expression Level on Cycle 1 Day 8 and Cycle 1 Day 21 Relative to That at Baseline
ratioPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor Participants
Cycle 1 Day 80.3 ± 0.240.1 ± 0.14
Cycle 1 Day 210.3 ± 0.330.0 ± 0.02
SecondaryChanges From Baseline in Notch Intracellular Domain (NICD) Levels in Peripheral Blood for T-ALL/LBL Participants

Notch intracellular domain (NICD) levels was measured in peripheral blood mononuclear cell (PBMC) pellets using a validated enzyme-linked immunosorbent assay (ELISA).

Time frame:
Baseline, Cycle 1 Days 8 and 15 (pre-dose AM), Cycle 1 Day 21 (pre-dose AM and 24, 48 and 120 hr post-dose) and end of treatment (EOT).

No measurements were reported for this outcome.

SecondaryChanges From Baseline in Notch Intracellular Domain (NICD) Levels in Bone Marrow for T-ALL/LBL Participants

Notch intracellular domain (NICD) was to be measured in bone marrow monoculear cell (BMMC) cell pellets using a validated ELISA.

Time frame:
Baseline, Cycle 1 Day 1 and Cycle 2 Day 1

No measurements were reported for this outcome.

Post-hocTime to Response (TTR) for Solid Tumor Participants

Time to response (TTR) was only defined for participants with an objective response (OR). TTR (months) was calculated as (date of first documentation of PR or CR minus date of first dose of study medication plus 1) divided by 30.

Time frame:
Baseline, Cycle 2 Day 1, Cycle 3 Day 1 and then Day 1 (+ or -5 days) of every odd cycle or as clinically indicated, up to Cycle 9. Afterwards, assessed on Day 1 (+ or -5 days) every 4 cycles.
Reported as:
Median · months
Time to Response (TTR) for Solid Tumor Participants
monthsPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
Time to Response (TTR) for Solid Tumor Participants11.2 (NA to NA)19.4 (8.5 to 30.4)2.9 (NA to NA)10.1 (NA to NA)5.9 (NA to NA)

Adverse events

Collected over Baseline up to end of study (maximum of 84 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-03084014 20 mg BID in Solid Tumor Participants—1/3 (33.3%)3/3 (100%)
PF-03084014 40 mg BID in Solid Tumor Participants—1/3 (33.3%)3/3 (100%)
PF-03084014 80 mg BID in Solid Tumor Participants—2/4 (50%)4/4 (100%)
PF-03084014 100 mg BID in Solid Tumor Participants—4/8 (50%)7/8 (87.5%)
PF-03084014 130 mg BID in Solid Tumor Participants—2/4 (50%)3/4 (75%)
PF-03084014 150 mg BID in Solid Tumor Participants—8/23 (34.8%)23/23 (100%)
PF-03084014 150 mg BID in T-ALL/LBL Participants—4/8 (50%)8/8 (100%)
PF-03084014 220 mg BID in Solid Tumor Participants—7/16 (43.8%)16/16 (100%)
PF-03084014 330 mg BID in Solid Tumor Participants—2/3 (66.7%)3/3 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
GRAM POSITIVE COCCIInvestigations0/30/30/40/80/40/230/80/161/2
NauseaGastrointestinal disorders0/30/30/40/82/40/80/80/160/2
SepsisInfections and infestations0/30/30/40/80/40/80/80/161/2
HypophosphataemiaMetabolism and nutrition disorders0/30/30/40/80/40/80/80/161/2
ConstipationGastrointestinal disorders1/30/30/40/80/40/80/80/160/2
DiarrhoeaGastrointestinal disorders1/30/30/40/81/40/80/80/160/2
Disease progressionGeneral disorders0/31/30/41/80/40/81/82/160/2
VomitingGastrointestinal disorders0/30/30/40/81/40/80/80/160/2
MalaiseGeneral disorders0/30/30/40/81/40/80/80/160/2
Joint dislocationInjury, poisoning and procedural complications0/30/31/40/80/40/80/81/160/2
Most frequent other events
Showing 10 of 222
Most frequent other events
EventPF-03084014 20 mg BID in Solid Tumor ParticipantsPF-03084014 40 mg BID in Solid Tumor ParticipantsPF-03084014 80 mg BID in Solid Tumor ParticipantsPF-03084014 100 mg BID in Solid Tumor ParticipantsPF-03084014 130 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in Solid Tumor ParticipantsPF-03084014 150 mg BID in T-ALL/LBL ParticipantsPF-03084014 220 mg BID in Solid Tumor ParticipantsPF-03084014 330 mg BID in Solid Tumor Participants
DiarrhoeaGastrointestinal disorders1/30/32/40/83/42/82/812/163/3
Decreased appetiteMetabolism and nutrition disorders2/32/30/41/81/47/80/83/161/3
NauseaGastrointestinal disorders2/30/31/42/83/45/85/88/162/3
HypophosphataemiaMetabolism and nutrition disorders0/30/32/42/82/46/80/89/161/3
FlatulenceGastrointestinal disorders2/31/30/40/80/41/80/80/160/3
VomitingGastrointestinal disorders0/30/31/42/82/45/85/85/162/3
FatigueGeneral disorders2/32/32/41/81/47/160/87/161/3
Mucosal inflammationGeneral disorders1/30/31/40/80/42/80/80/162/3
HeadacheNervous system disorders2/30/30/40/80/42/81/83/161/3
RashSkin and subcutaneous tissue disorders2/31/30/41/80/44/80/83/162/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)PF-03084014 in Solid Tumor ParticipantsPF-03084014 in T-ALL/LBL ParticipantsTotal
Mean55.6 ± 14.730.8 ± 952.9 ± 16.1
Sex: Female, Male
Sex: Female, Male(Participants)PF-03084014 in Solid Tumor ParticipantsPF-03084014 in T-ALL/LBL ParticipantsTotal
Female33235
Male31637
09

Study locations

10 sites
  • Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Denver CTRC
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Massachusetts General Hospital Clinical Laboratory
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02115, United States
  • Dana Ferber Cancer institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Center / Wayne State University
    Detroit, Michigan 48201, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
    Bologna, 40138, Italy
  • Istituto di Ematologia Seragnoli
    Bologna, 40138, Italy
10

References and documents

Publications

  • Papayannidis C, DeAngelo DJ, Stock W, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, Ozeck M, Aster JC, Kuo F, Huang D, Lira PD, McLachlan KR, Kern KA, Garcia-Manero G, Martinelli G. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015 Sep 25;5(9):e350. doi: 10.1038/bcj.2015.80. No abstract available. PubMed 26407235 ↗
  • Tabares-Seisdedos R, Rubenstein JL. Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci. 2013 Apr;14(4):293-304. doi: 10.1038/nrn3464. PubMed 23511909 ↗

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2009 to primary completion in Jan 2013, 42 months.

Results were first posted in Nov 2019, 6 years 10 months after primary completion.

Of 51 industry-sponsored phase 1 interventional studies under Leukemia, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 42 months is close to that.

Counting every sponsor, half of 164 studies reached it within 53 months; a quarter within 34 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2009
First posted
Apr 8, 2009
StartActual
Jun 25, 2009
Primary completionActual
Jan 10, 2013
CompletionActual
Nov 22, 2016
Results first posted
Nov 12, 2019
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00878189
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 8, 2009
Start date
Jun 25, 2009
Primary completion
Jan 10, 2013
Completion
Nov 22, 2016
Results posted
Nov 12, 2019
Last update
Nov 12, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion